November 26, 2016

AngioSoma Research Inc.

[cs_content][cs_section parallax=”false” style=”margin: 0px;padding: 45px 0px 5px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][cs_text][dropcap]A[/dropcap]ngioSoma, Inc. has a robust product pipeline, with patents, provisional patents, expired patents with corporate intellectual property / knowledge, registered trademarks, and many more to come. AngioSoma’s aggressive mission objective research efforts have led to the company’s most important current corporate assets that contribute to the shareholder value.[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” style=”margin: 0px;padding: 5px 0px 45px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 10px 0px 40px;”][x_custom_headline level=”h2″ looks_like=”h3″ accent=”false”]Products in Pipeline[/x_custom_headline][x_gap size=”50px”][x_image type=”rounded” src=”http://s642097301.onlinehome.us/wp-content/uploads/2016/08/soan-liprostin.png” alt=”” link=”true” href=”http://s642097301.onlinehome.us/liprostin” title=”Liprostin pads – AngioSoma” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][cs_text class=”cs-ta-left”] Liprostin™, AngioSoma, Inc.’s flagship product in its product pipeline, is a Peripheral Artery Disease (‘PAD‘) therapy using FDA approved Alprostadil™ (a prostaglandin, referred to as PGE-1) packaged inside a proprietary Liposome for controlled drug release. Learn More…
[/cs_text][x_gap size=”70px”][x_image type=”rounded” src=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/Transdermal-Patch-184X184-for-website.jpg” alt=”” link=”true” href=”http://s642097301.onlinehome.us/transdermal-patch” title=”Transdermal PGE-1 Patch – AngioSoma” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][cs_text class=”cs-ta-left”]
Transdermal PGE-1 Patch

In September 2016, AngioSoma, Inc. with its Chairman Emeritus David P. ‘Doc‘ Summers PhD filed 2 provisional U.S. Patents and 2 non-provisional U.S. Patents (announced October 11, 2016 in a press release entitled ‘AngioSoma, Inc. Files 3 New Patent Applications on Liprostin™). Learn More…
[/cs_text][x_gap size=”70px”][x_image type=”rounded” src=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/OmniCath-1-drawing-AngioSoma-ticker-SOAN.png” alt=”” link=”true” href=”http://s642097301.onlinehome.us/transdermal-patch” title=”Transdermal PGE-1 Patch – AngioSoma” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][cs_text class=”cs-ta-left”]

OmniCath I & OmniCath II

AngioSoma, Inc., a publicly traded Nevada corporation (‘SOAN’), and its subsidiary AngioSoma Research, Inc., a wholly owned Texas subsidiary, own patents associated with the OmniCath® I atherectomy catheter, protected by a U.S. Patent 5,728,129 issued on March 17th, 1998. SOAN is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath® II. Learn More…
[/cs_text][x_gap size=”70px”][x_image type=”rounded” src=”http://s642097301.onlinehome.us/wp-content/uploads/2016/11/AngioSoma-product-800px-Nicotine-3D-vdW-21-200w.png” alt=”” link=”true” href=”http://s642097301.onlinehome.us/transdermal-patch” title=”Transdermal PGE-1 Patch – AngioSoma” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][cs_text class=”cs-ta-left”]

SOMA Nutraceuticals, Inc.

SOMA Nutraceuticals, Inc., a Texas wholly owned subsidiary of AngioSoma, Inc., provides nutraceutical products, both patented and proprietary formulated, that integrate fully into AngioSoma, Inc.’s mission statement of having a complete solution for the treatment of cardiovascular disease – prior to the need for treatment to prevent the need for treatment (SOMA Nutraceuticals, Inc.), at treatment to bring patients up to a foundational level (Liprostin™ and the OmniCath I & II), and once patients have gotten to a foundational level to keep them at that level (the Transdermal PGE-1 Patch). Learn More…
[/cs_text][/cs_column][/cs_row][/cs_section][/cs_content]